P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

por Askeland, F. B., Haukås, E., Slørdahl, T. S., Schjøll, D., Lysen, A., Hermansen, E., Schjesvold, F.
Publicado 2022

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)

por Askeland, F. B., Rasmussen, A.-M., Lysen, A., Haukås, E., Eilertsen, A., Moksnes, M., Tsykunova, G., Vik, A., Eiken, B. D., Sørbø, J. H., Rolke, J., Sand, K. O., Hallstensen, R. F., Myrseth, L., Slørdahl, T. S., Schjesvold, F.
Publicado 2022

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESUL...

por Groen, K., Seefat, M. R., van der Holt, B., Schjesvold, F. H., Stege, C. A., Levin, M.-D., Hansson, M., Leys, R. B., Regelink, J., Waage, A., Szatkowski, D., Axelsson, P., Do, T. H., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C., Mellqvist, U.-H., van de Donk, N. W., Sonneveld, P., Klostergaard, A., Vangsted, A. J., Abdilgaard, N., Zweegman, S.
Publicado 2022